about
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.A phase I study of resminostat in Japanese patients with advanced solid tumors.Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancerA novel serum metabolomics-based diagnostic approach to pancreatic cancer.Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancerPicoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase InhibitorsValidity of new methods to evaluate renal function in cancer patients treated with cisplatinPharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphismPhase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumorsEfficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumorsSafety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in JapanSurveillance of protocol deviations in Japanese oncology registration trials: a single institute experience.Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma.Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses.Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions.PD-L1 expression in neuroendocrine tumors of the lung.Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
P50
Q33383835-4E52E2D1-E737-40E7-A3F5-EC69EFC26730Q33385245-96216FAD-0C29-457F-BBB8-9AD50718FE64Q33421741-05904479-BE9E-4022-80FA-0D57C7276E9AQ33424869-42744F20-092C-4E54-90DA-61A6A47EA763Q33426444-28014136-89A4-46E7-AED1-753CD052EBB6Q33428061-C572B104-6E55-4AC2-9CA5-DCFED32A7DBCQ33428122-F5412D9C-8D84-499A-8787-83681B4A42E8Q34046633-C4A6C0CF-1F9D-48C4-8340-E43A3D77CFBCQ34549970-DF01FBF9-E835-4AD2-8E7C-8E981423EFAEQ34642793-879091BE-CB22-4972-99EC-4493AE7713D3Q35817265-73ACA3BE-5A75-4FC0-8510-3BA748FF2E47Q35872968-3108DDE1-FF5D-4B82-B003-ACF96CB60003Q35947278-EFD1EFDB-E5BC-409F-9FEE-E070E7B0EAE0Q36262860-E2B05AD9-495B-4624-BDAA-ABEB56AE0D97Q36558400-9597E0C6-6E09-44DA-8BA9-6FAE07AC4B78Q36564270-7B498771-DCF1-44AF-8D41-C0026394D44EQ37170724-A680DA9C-52E0-4FDF-890E-49CF8F4AD73BQ37222786-64630D5E-C769-4E8B-8387-A5968B5FB8F2Q37362867-2ADD292A-B42B-4FFE-AC36-80CCA35C0ACFQ37375259-CE6415B0-BA57-4884-A5FA-24DBEFBDEF00Q37526782-9D678807-0D83-429B-82E0-DCCCC5BF159FQ38400938-5E56C021-F1D1-4F92-BEE9-CB61847C4F23Q38742640-B3C80F7F-E620-4AEB-AA86-614D3146A3F8Q38907890-6EAF1553-42B2-4723-8090-AC718B5D58CFQ39114679-C74CF55B-E212-48C1-A4D0-222C655FEF62Q39219590-8A457505-5097-44FF-8D40-088CAF0B036CQ39308771-4749A85A-960D-49A9-8B3E-34466EA92028Q39344908-16DD5941-61EC-40AC-81C6-FE161C57C2C8Q40174958-55963190-E2CF-444C-93F9-9CF575AD8168Q40897244-81DABCE5-3DB6-4215-8230-7669DC1D5E9BQ41006758-7A294503-C488-4C0D-B731-01E704D62F26Q41110633-0821681E-0689-45D0-966B-0CC2B0588A02Q41382716-0C59399C-2639-48DF-9FC9-9857D54180CDQ43182339-95DF7EE6-FF85-4EBD-9141-B1ECBB5BAB05Q45148789-EC3A03D3-6237-423E-B9C8-3E24BE65C71DQ47712432-8713EF6D-2A50-45A9-991D-5F7C734E0DC8Q47726448-924E311F-2690-4BCD-BBAF-27E16563F6C8Q47895887-4A4C0A02-4C9E-434E-8926-56DB6B576055Q48003216-397948EC-B2D7-4D2D-83CA-CB0344878A63Q48108178-786A8FE4-992F-47C9-83D7-1D0360A734A7
P50
description
researcher ORCID ID = 0000-0001-6981-0800
@en
wetenschapper
@nl
name
Yutaka Fujiwara
@ast
Yutaka Fujiwara
@en
Yutaka Fujiwara
@es
Yutaka Fujiwara
@nl
type
label
Yutaka Fujiwara
@ast
Yutaka Fujiwara
@en
Yutaka Fujiwara
@es
Yutaka Fujiwara
@nl
prefLabel
Yutaka Fujiwara
@ast
Yutaka Fujiwara
@en
Yutaka Fujiwara
@es
Yutaka Fujiwara
@nl
P106
P31
P496
0000-0001-6981-0800